



(51) International Patent Classification:

A61K 31/198 (2006.01) *A61K 9/00* (2006.01)
A61K 31/4172 (2006.01) *A61K 45/06* (2006.01)
A61K 38/05 (2006.01) *A61K 9/107* (2006.01)
A61K 38/07 (2006.01) *A61K 47/18* (2017.01)
A61P 17/00 (2006.01)

(21) International Application Number:

PCT/EP2021/077931

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20201040.1 09 October 2020 (09.10.2020) EP

(71) Applicant: **MC2 THERAPEUTICS LTD** [GB/GB];
 James House Emlyn Lane, Leatherhead KT22 7E (GB).

(72) Inventors: **MENNE, Torkil**; c/o MC2 Therapeutics Ltd,
 James House, Emlyn Lane, Leatherhead KT22 7E (GB).
SELMER, Johan; c/o MC2 Therapeutics Ltd, James

House, Emlyn Lane, Leatherhead KT22 7E (GB). **LANGE, Jesper**; c/o MC2 Therapeutics Ltd, James House, Emlyn Lane, Leatherhead KT22 7E (GB). **BONDEBJERG, Jon**; c/o MC2 Therapeutics Ltd, James House, Emlyn Lane, Leatherhead KT22 7E (GB). **GEORGIU, Michelle**; c/o MC2 Therapeutics Ltd, James House, Emlyn Lane, Leatherhead KT22 7E (GB).

(74) Agent: **INSPICOS P/S**; Kogle Allé 2, 2970 Hørsholm (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: TREATMENT OF DERMATOLOGICAL CONDITIONS




FIG. 1

(57) Abstract: Provided is a pharmaceutical composition which comprises a nucleophilic compound capable of inhibiting carbamylation, for use in the treatment of a condition involving cutaneous or connective tissue damage. A method for treating a condition involving cutaneous or connective tissue damage in a patient, is also provided, said method comprising administering a said pharmaceutical composition to said patient.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*